# Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.

> **NCT01956903** · PHASE1,PHASE2 · COMPLETED · sponsor: **Grupo Espanol de trasplantes hematopoyeticos y terapia celular** · enrollment: 15 (actual)

## Conditions studied

- Chronic Graft-Versus-Host Disease

## Interventions

- **GENETIC:** Allogenic Mesenchymal Stem Cell

## Key facts

- **NCT ID:** NCT01956903
- **Lead sponsor:** Grupo Espanol de trasplantes hematopoyeticos y terapia celular
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01956903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01956903, "Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01956903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*